The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adjuvant paclitaxel followed by oral fluoropyrimidines for gastric cancer: Safety data of the factorial phase III SAMIT trial.
Michiya Kobayashi
No relevant relationships to disclose
Akira Tsuburaya
No relevant relationships to disclose
Kazuhiro Yoshida
No relevant relationships to disclose
Shigefumi Yoshino
No relevant relationships to disclose
Yumi Miyashita
No relevant relationships to disclose
Satoshi Morita
No relevant relationships to disclose
Koji Oba
No relevant relationships to disclose
Marc E. Buyse
No relevant relationships to disclose
John S. Macdonald
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose